文献速递妇科

I期恶性卵巢生殖细胞肿瘤保留生育功能卵巢囊肿切除术的应用与结局

Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors.
PubMed 文献 · Gynecol Oncol · 2025-12-24

基于美国国家癌症数据库2004至2022年1345例I期恶性卵巢生殖细胞肿瘤患者,151例(11.2%)行囊肿切除术、1194例(88.8%)行单侧输卵管卵巢切除术。囊肿切除术使用率从2004年18.4%降至2022年9.4%(P<0.0001,APC=-5.5%)。倾向评分加权后,囊肿切除术与单侧输卵管卵巢切除术相比总生存无显著差异,调整后2年生存率99.7%对100.0%,5年生存率98.7%对98.4%,总死亡调整后风险比0.70(95%CI 0.21-2.33)。

要点

  • I期恶性卵巢生殖细胞肿瘤中囊肿切除术使用率从2004年18.4%降至2022年9.4%(P<0.0001,APC=-5.5%)。
  • 囊肿切除术组接受淋巴结清扫的比例低于单侧输卵管卵巢切除术组(21.4%对35.3%,SMD=0.32)。
  • 调整后囊肿切除术与单侧输卵管卵巢切除术相比总生存无显著差异,总死亡风险比0.70(95%CI 0.21-2.33)。

核心结论

  • I期恶性卵巢生殖细胞肿瘤的囊肿切除术使用率随时间下降。
  • 接受囊肿切除术的患者估计总生存与单侧输卵管卵巢切除术相比无显著差异,包括按组织学亚型和年龄分层分析。

研究设计与样本

  • 使用美国国家癌症数据库识别2004至2022年年龄18至49岁、接受囊肿切除术或单侧输卵管卵巢切除术的I期恶性卵巢生殖细胞肿瘤女性。
  • 采用对数线性回归识别与囊肿切除术相关的因素。
  • 采用倾向评分逆概率处理加权(IPTW-ATT)估计囊肿切除术与单侧输卵管卵巢切除术与生存的关联,使用加权Cox比例风险模型和Kaplan-Meier曲线。

主要发现

  • 共1345例患者,1194例(88.8%)行单侧输卵管卵巢切除术,151例(11.2%)行囊肿切除术。
  • 囊肿切除术使用率从2004年18.4%降至2022年9.4%(P<0.0001,APC=-5.5%)。
  • 囊肿切除术在混合性生殖细胞肿瘤和社区癌症项目中更常见。
  • 囊肿切除术组接受淋巴结清扫的比例低于单侧输卵管卵巢切除术组(21.4%对35.3%,SMD=0.32),辅助化疗使用两组相似。
  • 调整后2年生存率单侧输卵管卵巢切除术组99.7%对囊肿切除术组100.0%,5年生存率单侧输卵管卵巢切除术组98.7%对囊肿切除术组98.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Treatment for malignant ovarian germ cell tumors {MOGCTs) in women desiring fertility preservation is typically unilateral salpingo-oophorectomy (USO). While small studies have examined cystectomy for immature teratomas, larger-scale data are limited. We evaluated use and survival outcomes of cystectomy versus USO for stage I MOGCTs. METHODS: Using the National Cancer Database, we identified women aged 18-49 with stage I MOGCTs who underwent cystectomy or USO from 2004 to 2022. Log-linear regression identified factors associated with cystectomy. Propensity score inverse probability of treatment weighting (IPTW) for average treatment effect on the treated (IPTW-ATT) was applied to estimate the association of cystectomy versus USO with survival using weighted Cox proportional hazards models and Kaplan-Meier curves. RESULTS: Among 1345 patients, 1194 (88.8 %) underwent USO and 151 (11.2 %) cystectomy. Cystectomy use declined from 18.4 % (2004) to 9.4 % (2022) (P < 0.0001, APC = -5.5 %). Cystectomy was more common in mixed germ cell tumors and at community cancer programs. Patients who underwent cystectomy were less likely to receive lymphadenectomy (21.4 % vs. 35.3 %, SMD = 0.32), while adjuvant chemotherapy use was similar between groups. Adjusted 2-year survival was 99.7 % (USO) vs. 100.0 % (cystectomy), and 5-year survival was 98.7 % (USO) vs. 98.4 % (cystectomy). Adjusted hazard ratio for overall mortality was 0.70 (95 %CI: 0.21-2.33) for cystectomy versus USO. Stratified analyses by histology and age showed no survival differences. CONCLUSION: Cystectomy use for stage I MOGCT has declined over time. Among patients who underwent cystectomy, estimated overall survival did not differ significantly from that expected of USO, including across histologic subtypes and age.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ludmir D, Huang Y, Xu X, et al. Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors. Gynecol Oncol. 2025. PMID: 41448116. doi:10.1016/j.ygyno.2025.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。